Clinical Trials Registration
toxic, breast cancer
BREAST CANCER
NCT03991013.Among adults switching to second-line tenofovir-lamivudine-dolutegravir with unsuppressed HIV-1 RNA levels and substantial baseline nucleoside reverse transcriptase inhibitor resistance, a high proportion achieved virologic suppression.Clinical Trials Registration. NCT03991013Dolutegravir with 2 nucleoside reverse transcriptase inhibitors (NRTIs) is the World Health Organization (WHO)–recommended second-line antiretroviral therapy (ART) regimen for adults failing first-line regimens based on the nonnucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine or efavirenz [Tenofovir is less toxic than zidovudine [Efavirenz induces drug metabolizing enzymes (UGT1A1 and CYP3A4) and transporters (P-glycoprotein and breast cancer resistance protein), which decreases dolutegravir exposure [We previously conducted a prospective cohort study of recycled tenofovir and lamivudine with dolutegravir in second-line ART with a supplementary dolutegravir dose (50 mg twice daily) for 2 weeks to overcome efavirenz induction, and 85% achieved virologic suppression at week 24, despite 65% having resistance to both tenofovir and lamivudine at baseline [